ArticleEye (London, England)2026
Persistent fluid, persistent risk: predicting pachychoroid macular atrophy in chronic central serous chorioretinopathy.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify clinical and anatomical predictors of pachychoroid macular atrophy (pMA) development in chronic central serous chorioretinopathy (CSC) patients treated with photodynamic therapy (PDT), eplerenone, or subthreshold micropulse laser (SMLT).
methodsRetrospective study of 74 consecutive chronic or recurrent CSC patients. All underwent baseline multimodal imaging and were treated with PDT (half-dose), eplerenone (50 mg daily), or SMLT (577 nm), per clinical protocols. Retreatment during follow-up with PDT or MLT was performed as needed based on fluid persistence or recurrence. Quantitative (SRF height, SFCT, CRT) and qualitative (SRF, SHRM, PED, EZ integrity) OCT parameters were recorded. Multivariate regression identified independent predictors of pMA, adjusting for treatment modality.
resultsAt 12-month follow-up, persistent SRF was found in 51.4% of patients and was the strongest independent predictor of pMA (OR = 14.07; 95% CI: 1.73-114.65; p = 0.001). Additional independent predictors included reduced SRF height change (OR = 2.31; 95% CI: 1.14-4.68; p = 0.021), pronounced subfoveal choroidal thinning (OR = 1.68; 95% CI: 1.02-2.77; p = 0.045), and persistent SHRM (OR = 3.24; 95% CI: 1.32-7.95; p = 0.010). Treatment modality (PDT, eplerenone, SMLT) was not a significant independent predictor of pMA when adjusted for fluid persistence (p > 0.05).
conclusionsIn chronic CSC, persistent subretinal fluid after treatment-regardless of retreatment-remains the dominant predictor of pMA. Anatomical resolution of SRF should be a primary therapeutic goal to prevent irreversible atrophic damage.
Identifiers
42562867What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.